AbCellera is a leading international biotechnology firm with over $375MM in annual revenue and partnerships including Pfizer, Merck, Novartis and GlaxoSmithKline.
Business Challenges
- Disconnected Planning Environment: Legacy forecasting processes for P&L, Balance Sheet, and Cash Flow were highly manual and timeconsuming, increasing risk and reducing agility.
- Separated Data: Financial and operational data resided across multiple platforms and offline sources, making it difficult to automate and
scale business processes. - Clinical Trial Planning and Patient Forecasting: Existing tools lacked the capability to cross-reference financials with clinical planning,
limiting visibility across functions and impacting strategic planning.
Solution
- Integrated Data Hub Modeling: Built a centralized Data Hub in Anaplan to consolidate data from Sage Intacct, ADP Workforce Now, and
offline sources, providing a unified foundation for planning. - Holistic Forecasting Models: Implemented Anaplan models for P&L, Balance Sheet, and Cash Flow forecasting, supporting both operational
planning and financial alignment. - Clinical and Patient Planning Enablement: Enabled patient forecasting and clinical trial planning to be modeled alongside financial data for
end-to-end planning visibility. - Platform Scalability: Established a flexible architecture designed to grow with AbCellera’s evolving needs, from clinical operations to
corporate finance.
Impact
- Streamlined Forecasting Process: Reduced manual data handling and improved forecast accuracy through integrated data flows and
automated model logic. - Cross-Functional Visibility: Enabled finance and clinical operations to collaborate using a single planning environment, improving alignment
and decision-making. - Improved Scalability & Readiness: Positioned AbCellera for future growth by implementing a scalable, automated platform that supports
both current needs and long-term expansion.
